Form 4: Vor Biopharma Officer Eyal C. Attar Reports Sale of Common Stock
SEC Form 4 Filing
Eyal C. Attar, Chief Medical Officer of Vor Biopharma Inc., reported selling 2,554 shares of common stock at an average price of $1.37 on February 10, 2025, according to a Form 4 filing.
Summary
- On February 10, 2025, Eyal C. Attar, the Chief Medical Officer of Vor Biopharma Inc., sold 2,554 shares of common stock.
- The sale was executed at a weighted average price of $1.37 per share.
- The transactions occurred at prices ranging from $1.33 to $1.42.
- Following the reported transaction, Attar directly owns 128,852 shares of Vor Biopharma Inc.
- The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 4, 2024.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports a routine stock sale by an officer under a pre-arranged trading plan. There is no indication of positive or negative implications for the company.
Industry Context
This filing is a routine disclosure of insider trading activity. It provides transparency to the market regarding the transactions of company executives.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders due to the increased supply of shares in the market.
Key Dates
| Date | Description |
|---|---|
| 2024/03/04 | Date of adoption of Rule 10b5-1 trading plan |
| 2025/02/10 | Date of stock sale transaction |
| 2025/02/12 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.